Latest Trials Latest NewsFAQ

ABBVIE

🇫🇷France

Country: 🇫🇷France

Ownership: -

Established: 2013-01-01

Employees: -

Market Cap: $346B

Website: http://www.abbvie.com

Clinical Trials

A Study of Viekira/Exviera for Korean Hepatitis C Patients According to the Standard for Re-examination of New Drugs

Completed

Conditions: Hepatitis C Virus (HCV)

First Posted Date: 2017-06-28

Last Posted Date: 2020-10-08

Lead Sponsor: AbbVie

Target Recruit Count: 505

Registration Number: NCT03201718

Locations: 🇰🇷
Kyungpook National Univ Hosp /ID# 168731, Daegu, Daegu Gwang Yeogsi, Korea, Republic of
🇰🇷
Dong-A University Hospital /ID# 167362, Busan, Busan Gwang Yeogsi, Korea, Republic of
🇰🇷
Yeungnam University Med Ctr /ID# 167425, Daegu, Daegu Gwang Yeogsi, Korea, Republic of

and more 56 locations

A Study of Venetoclax in Combination With Navitoclax and Chemotherapy in Subjects With Relapsed/Refractory Acute Lymphoblastic Leukemia or Relapsed/Refractory Lymphoblastic Lymphoma

Phase 1

Completed

Conditions: Lymphoblastic Lymphoma
Acute Lymphoblastic Leukemia (ALL)

Interventions: Drug: Navitoclax
Drug: Chemotherapy
Drug: Venetoclax

First Posted Date: 2017-06-08

Last Posted Date: 2021-10-14

Lead Sponsor: AbbVie

Target Recruit Count: 69

Registration Number: NCT03181126

Locations: 🇺🇸
City of Hope /ID# 169029, Duarte, California, United States
🇺🇸
LPCH Stanford /ID# 163337, Palo Alto, California, United States
🇺🇸
University of Chicago /ID# 163369, Chicago, Illinois, United States

and more 12 locations

A Study Evaluating the Safety and Efficacy of Upadacitinib in Adults With Active Ankylosing Spondylitis

Phase 2

Completed

Conditions: Ankylosing Spondylitis (AS)

Interventions: Drug: Upadacitinib
Drug: Placebo

First Posted Date: 2017-06-07

Last Posted Date: 2023-03-07

Lead Sponsor: AbbVie

Target Recruit Count: 187

Registration Number: NCT03178487

Locations: 🇸🇪
Reumatologkliniken /ID# 165713, Vaesteras, Sweden
🇺🇸
Bay Area Arthritis and Osteo /ID# 165023, Brandon, Florida, United States
🇺🇸
St. Lukes Clinic /ID# 165827, Meridian, Idaho, United States

and more 98 locations

Impact of Humira® Therapy on Ocular Inflammation, Selected Health Care Resource Utilization and Patient Reported Outcomes in Patients With Active Non-infectious Intermediate, Posterior and Panuveitis in Routine Clinical Practice

Completed

Conditions: Uveitis

First Posted Date: 2017-05-16

Last Posted Date: 2021-02-11

Lead Sponsor: AbbVie

Target Recruit Count: 155

Registration Number: NCT03155243

Locations: 🇦🇹
Medizinische Universität Graz /ID# 206301, Graz, Steiermark, Austria
🇦🇹
Medical University of Vienna /ID# 206190, Vienna, Wien, Austria
🇨🇴
Clinica Oftalmologica del Caribe /ID# 206448, Barranquilla, Atlantico, Colombia

and more 25 locations

Efficacy and Safety of Dalbavancin Compared to Standard of Care Antibiotic Therapy for the Completion of Treatment of Patients With Complicated Bacteremia or Infective Endocarditis

Phase 2

Terminated

Conditions: Endocarditis
Bacteremia

Interventions: Drug: Standard of Care
Drug: Dalbavancin

First Posted Date: 2017-05-11

Last Posted Date: 2022-04-25

Lead Sponsor: AbbVie

Target Recruit Count: 2

Registration Number: NCT03148756

Locations: 🇺🇸
Midway Immunology and Research Center, Fort Pierce, Florida, United States

A Study Evaluating the Safety, Pharmacokinetics and Anti-Tumor Activity of ABBV-176 in Subjects With Advanced Solid Tumors Likely to Express Prolactin Receptor (PRLR)

Phase 1

Terminated

Conditions: Advanced Solid Tumors Cancer

Interventions: Drug: ABBV-176

First Posted Date: 2017-05-09

Last Posted Date: 2018-11-29

Lead Sponsor: AbbVie

Target Recruit Count: 19

Registration Number: NCT03145909

Locations: 🇺🇸
City of Hope /ID# 161079, Duarte, California, United States
🇺🇸
Yale University /ID# 201357, New Haven, Connecticut, United States
🇺🇸
St. Lukes Cancer Institute /ID# 201353, Kansas City, Missouri, United States

and more 8 locations

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ABBV-553 in Healthy Volunteers and in Subjects With Psoriasis and Efficacy of ABBV-553 in Subjects With Psoriasis

Phase 1

Terminated

Conditions: Psoriasis

Interventions: Drug: ABBV-553
Drug: Placebo

First Posted Date: 2017-05-09

Last Posted Date: 2017-11-06

Lead Sponsor: AbbVie

Target Recruit Count: 12

Registration Number: NCT03145948

Locations: 🇺🇸
Anaheim Clinical Trials LLC /ID# 164101, Anaheim, California, United States
🇺🇸
Providence Clinical Research /ID# 163867, Toluca, California, United States
🇺🇸
Abbvie Clinical Pharmacology Research Unit /ID# 163866, Grayslake, Illinois, United States

and more 1 locations

SC-004 Alone or With ABBV-181 in Subjects With Epithelial Ovarian, Fallopian Tube, Primary Peritoneal and Endometrial Cancers

Phase 1

Terminated

Conditions: Cancer

Interventions: Drug: SC-004
Drug: ABBV-181

First Posted Date: 2017-05-03

Last Posted Date: 2019-05-14

Lead Sponsor: AbbVie

Target Recruit Count: 24

Registration Number: NCT03138408

Locations: 🇺🇸
Highlands Oncology Group /ID# 209165, Fayetteville, Arkansas, United States
🇺🇸
City of Hope /ID# 202493, Duarte, California, United States
🇺🇸
The Ohio State University - Columbus /ID# 164089, Columbus, Ohio, United States

and more 9 locations

Expanded Access to Glecaprevir/ Pibrentasvir

Conditions: Hepatitis C Virus Infection

First Posted Date: 2017-04-21

Last Posted Date: 2020-01-18

Lead Sponsor: AbbVie

Registration Number: NCT03123965

Locations: 🇸🇮
Univ Medical Ctr Ljubljana /ID# 161419, Ljubljana, Slovenia

Expanded Access to Venetoclax

Conditions: Chronic Lymphocytic Leukemia (CLL)
Multiple Myeloma
Acute Myeloid Leukemia (AML)
Non-Hodgkin's Lymphoma
Acute Lymphoblastic Leukemia (ALL)
Amyloidosis
Plasma Cell Leukemia

First Posted Date: 2017-04-21

Last Posted Date: 2024-04-03

Lead Sponsor: AbbVie

Registration Number: NCT03123029

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy